Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer

  • Giuntini, Fabio
  • González-Larreategui, Íñigo|||0000-0002-0959-8497
  • Herencia-Ropero, Andrea|||0009-0002-9448-1484
  • Casacuberta-Serra, Sílvia|||0000-0002-2595-1115
  • Zacarías-Fluck, Mariano F.|||0000-0002-7171-4268
  • Arnal, Magdalena|||0000-0001-8647-9232
  • Pedretti, Flaminia
  • Martínez-Martín, Sandra|||0000-0003-4443-0697
  • Thabussot, Hugo
  • Cano, Virginia Castillo
  • Grueso, Judit|||0000-0003-1093-7940
  • Foradada Felip, Laia|||0000-0002-0589-4360
  • Serrano, Erika
  • López-Estévez, Sergio|||0000-0001-5355-8073
  • Rodriguez, Olga
  • Guzmán, Marta|||0000-0002-0924-9887
  • Rodriguez-Hernandez, Adela
  • Brasó-Maristany, Fara|||0000-0001-5440-9643
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Nonell, Lara|||0000-0002-8538-8213
  • Prat, Aleix|||0000-0003-2377-540X
  • Serra, Violeta|||0000-0001-6620-1065
  • Beaulieu, Marie-Eve|||0000-0001-5224-8436
  • Whitfield, Jonathan R.|||0000-0002-4925-7283
  • Massó Vallés, Daniel|||0000-0003-4231-0456
  • Soucek, Laura|||0000-0002-4750-7971
MYC is dysregulated in most human cancers and is a DNA damage response (DDR) modulator capable of both promoting genomic instability and enhancing DNA repair. Here, we show that Omomyc, the only direct MYC inhibitor that has completed a phase 1 trial, shuts down DDR genes in triple-negative breast cancer (TNBC), causing DDR defects and inducing DNA damage. Since DDR-deficient tumors are currently targeted by poly ADP-ribose polymerase inhibitors (PARPis), we tested combinations with Omomyc. We show that Omomyc-induced DNA damage is enhanced by PARPis and that the inhibitors cooperate even in models with intrinsic or acquired PARPi resistance, both in vitro and in vivo. Moreover, using patient-derived models and clinical samples, we reveal a role for MYC as a predictor of PARPi resistance. Overall, our research highlights the opportunity of combining MYC inhibition by Omomyc with PARPis in PARPi-resistant TNBC, where MYC transcriptional activity represents a predictive biomarker of resistance to therapy.